Association between Systemic Lupus Erythematosus and Coronary Heart Disease: a retrospective case-control analysis and Mendelian Randomization Study

ObjectivesTo appraise the causal effect of systemic lupus erythematosus (SLE) for risk of Coronary heart disease (CHD). MethodsWe selected single nucleotide polymorphisms (SNPs) associated with SLE as instrumental variables (IVs) from three independent genome-wide association studies (GWAS), the three largest to date for SLE of European ancestry. Then we conducted two-sample Mendelian randomization (2SMR) analyses to estimate the effects of IVs on the odds of CHD and traditional coronary risk factors (including high LDL cholesterol levels, low HDL cholesterol levels, Apolipoprotein A-I, Apolipoprotein B, diabetes mellitus, and hypertension). Additionally, we searched for common risk loci between SLE and premature coronary atherosclerosis. Furthermore, we retrospectively reviewed the lipid profile of treatment-naive SLE patients and age-matched healthy controls. ResultsGenetically predicted SLE did not increase the odds of CHD. Nevertheless, we found mild causal relationships between SLE and decreased HDL cholesterol levels, and between SLE and decreased apolipoprotein A-I. There was one common risk locus (rs597808) between SLE and premature coronary atherosclerosis at a genome-wide significance level (P<5 x 10-8). Retrospective analysis showed decreased HDL-cholesterol (0.98{+/-}0.516mmol/L vs. 1.46{+/-}0.307mmol/L in female, 0.76{+/-}0.199mmol/L vs. 1.19{+/-}0.257mmol/L in male; both P<0.001) and apolipoprotein A-I (1.06{+/-}0.314g/L vs. 1.37{+/-}0.205g/L in female, 0.87{+/-}0.174g/L vs. 1.24{+/-}0.200g/L in male; both P<0.001) in naive SLE patients. ConclusionSLE may accelerate coronary atherosclerosis in young patients by reducing HDL cholesterol and apolipoprotein A-I intrinsically, but it seems not to play a predominant role in CHD development in old patients.